Strong orders for proton therapy systems and linear accelerators helped Ion Beam Applications (IBA) achieve double-digit sales growth in 2015.
The company advanced total net sales 22% to 270.3 million euros last year, compared with 220.6 million euros in 2014.
Most of the company's revenues came from sales of proton therapy systems and linear accelerators, which increased 22% to 216.3 million euros in 2015, compared with 177.7 million euros in 2014.
Net profit rose 151% to 61.2 million euros, due in part to 32.5 million euros from other operating income, including a capital gain on the company's disposal of its IBA Molecular joint venture, which was divested to an investment firm this month.
